Evidence map›Paper›PMID 33738059›Full record

ArticleACS medicinal chemistry letters2021

Synthesis of HDAC Inhibitor Libraries via Microscale Workflow.

Kevin D Dykstra, Eric Streckfuss, Min Liu, Jian Liu, Younong Yu, Ming Wang, Joseph A Kozlowski, Robert W Myers, Alexei V Buevich, Milana M Maletic and 2 more

Abstract read
In one paragraph

Article in ACS medicinal chemistry letters, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. High-Throughput Photo- and Electrochemical spACS medicinal chemistry letters · 2023
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Kevin D DykstraChemical Capabilities for Accelerating Therapeutics, Merck & Co., Inc., Kenilworth, New Jersey 07033, United States.
Eric StreckfussDiscovery Chemistry, Merck & Co., Inc., West Point, Pennsylvania 19486, United States.
Min LiuChemical Capabilities for Accelerating Therapeutics, Merck & Co., Inc., Kenilworth, New Jersey 07033, United States.
Jian LiuScreening, Targets and Compound Profiling, Merck & Co., Inc., Kenilworth, New Jersey 07033, United States.
Younong YuChemical Capabilities for Accelerating Therapeutics, Merck & Co., Inc., Kenilworth, New Jersey 07033, United States.
Ming WangChemical Capabilities for Accelerating Therapeutics, Merck & Co., Inc., Kenilworth, New Jersey 07033, United States.
Joseph A KozlowskiDiscovery Chemistry, Merck & Co., Inc., Kenilworth, New Jersey 07033, United States.
Robert W MyersPharmacokinetics, Pharmacodynamics and Drug Metabolism, Merck & Co., Inc., Kenilworth, New Jersey 07033, United States.
Alexei V BuevichNMR Structure Elucidation, Merck & Co., Inc., Kenilworth, New Jersey 07033, United States.
Milana M MaleticChemical Capabilities for Accelerating Therapeutics, Merck & Co., Inc., Kenilworth, New Jersey 07033, United States.
Petr VachalScreening, Targets and Compound Profiling, Merck & Co., Inc., Kenilworth, New Jersey 07033, United States.
Shane W KrskaChemical Capabilities for Accelerating Therapeutics, Merck & Co., Inc., Kenilworth, New Jersey 07033, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

An integrated workflow has been established that enables the synthesis, purification, and subsequent biological testing of compound libraries on a microgram scale. This approach utilizes mass directed preparative HPLC in conjunction with charged aerosol detection (CAD) to generate solutions of investigational compounds at high purity and standardized concentrations, facilitating high fidelity biological testing. This new workflow successfully delivered libraries of histone deacetylase (HDAC) inhibitors that afforded biological data consistent with that obtained from standard scale parallel medicinal chemistry techniques. The advantages of this new approach to library synthesis include greatly reduced material requirements and amenability to high-throughput experimentation.

Identifiers

PMID33738059
PMCPMC7957937

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.